Dy­nacure to merge with Flamin­go, re­join­ing two Io­n­is-af­fil­i­at­ed biotechs

Dy­nacure still isn’t get­ting on­to the pub­lic mar­kets, but the French-US biotech is com­bin­ing with an­oth­er Io­n­is-al­lied drug de­vel­op­er to stay afloat.

Af­ter its lead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER